Prolonged activated partial thromboplastin time predicts poor short-term prognosis in patients with acute pancreatitis: A retrospective cohort study

Yuping Yang | Shenshen Du | Weinan Yuan | Yanqi Kou | Biao Nie

Abstract
It is unclear whether activated partial thromboplastin time (APTT) is predictive of survival in patients with acute pancreatitis (AP). Our study aimed to investigate the relationship between APTT and short-term prognosis in AP. From the Medical Information Mart for Intensive Care (MIMIC)-IV database, a total of 844 patients with AP were randomly divided into the training cohort (n = 591) and the validation cohort (n = 253) at a ratio of 7:3. Based on their APTT values, the patients were divided into the normal and high groups. The primary outcome of this study was 30- and 60-day survival. Kaplan–Meier survival analysis and Cox regression models were used to analyze associations between groups and outcomes. The training and validation cohort matched well on all parameters (p > 0.05). In terms of 30- and 60-day survival, Kaplan–Meier survival curves from both training and validation cohorts demonstrated a lower survival probability for patients in the high APTT group than the normal group (log-rank p < 0.05). In the training cohort, patients in the high APTT group had a statistically significantly higher risk of death than those in the normal group after controlling for possible confounders in Cox regression (p < 0.05). For the high APTT group, the hazard ratios (95% confidence interval [CI]) were 1.63 (95% CI 1.10, 2.61, p = 0.035) and 1.49 (95% CI 1.01, 2.38, p = 0.041), respectively. APTT performed as well as BISAP, Ranson, and APACHE II models in predicting 30- and 60-day survival in patients with AP. The results above have been verified in the validation cohort. Prolonged APTT in patients with AP may increase the risk of short-term death.

Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? The lack of biomarkers for predicting the short-term prognosis of acute pancreatitis (AP) is a significant problem. Patients with AP are often suffering from coagulation disorders. Activated partial thromboplastin time (APTT) is a biomarker that represents the endogenous coagulation pathway. This study was designed...
INTRODUCTION

Acute pancreatitis (AP) is among the most common gastroenterological conditions that result in hospitalization in the intensive care unit (ICU).1 AP is a complicated disease with varying severity and course. It remains a significant cause of death.2 In patients with biliary AP, hepcidin and systemic inflammatory response syndrome may predict patient prognosis.3 Using serum hydroxybutyrate dehydrogenase early in the course of AP may help predict its severity.4 Increased arterial blood lactic acid concentration is associated with increased 28-day mortality in patients with severe AP.5 Proper management depends on prompt diagnosis and severity classification. Scoring systems are useful adjuncts but should not replace clinical judgment. Thus, early diagnosis and management of death-related risk factors may improve outcomes in patients with AP.

Despite some limitations, the bedside index for severity in acute pancreatitis (BISAP), Acute Physiology and Chronic Health Examination (APACHE)-II, computed tomography severity index (CTSI), and Ranson criteria are most commonly used to determine the prognosis of AP.6–8 The BISAP score is an effective tool for risk stratification in patients with AP. It contains clinically relevant and easily accessible components. BISAP scores are comparable in prognostic accuracy to the results of other scoring systems, even better than Ranson criteria and CTSI.6,9 Activated partial thromboplastin time (APTT), BISAP, Ranson, and APACHE II were compared in this study for their potential ability to predict short-term prognosis of patients with AP.

Activated partial thromboplastin time is the most common test to screen endogenous coagulation disorders. When there is a deficiency in coagulation factors or coagulation dysfunction, APTT is prolonged.10 In patients with sepsis, mortality increases in patients with prolonged APTT.11 Prolonged APTT also results in more severe organ failure in patients with sepsis.12 Furthermore, prolonged APTT is associated with a higher risk of mortality in patients admitted to the ICU.13 However, it remains unclear whether prolonged APTT is related to short-term prognosis in patients with AP.

MATERIALS AND METHODS

Data source

The data for this retrospective cohort study were obtained from the Medical Information Mart for Intensive Care (MIMIC)-IV database between 2008 and 2019.14 All personal information about the patients was re-coded following the Health Insurance Portability and Accountability Act, and all identifiable information was omitted. Thus, informed consent is not needed from the patients. The MIMIC-IV project was approved by the ethics committees of the Massachusetts Institute of Technology (United States) and Beth Israel Deaconess Medical Center (United States), and the first author and corresponding author have been approved as authorized users for access to the MIMIC-IV database (first author...
The study was performed to comply with the Declaration of Helsinki principles.

**Participants**

From the MIMIC IV database, 1033 patients admitted to the ICU for an AP exacerbation were extracted. Among these patients are those who suffer from alcoholic AP, biliary AP, drug-induced AP, and unspecified AP. The exclusion criteria were as follows: patients who died within 24 h in the ICU, patients younger than 18 years old, patients with more than one ICU admission, patient with hemophilia, patients without APTT records, patients with APTT records 23. In the end, a total of 844 patients with AP were selected for the study. Moreover, they were randomly divided into the training cohort (n = 591) and the validation cohort (n = 253) at a ratio of 7:3 (Figure 1). Because the normal ranges for APTT values are 23–37, patients with an APTT value of 23–37 were selected in the normal APTT group, and those with a value >37 were chosen in the high APTT group.

**Data extraction**

For this retrospective cohort study, the extracted variables included sex, age, medical history, the condition assessment record form, routine blood tests, routine biochemical tests, use of vasopressors, duration of ICU stay and hospital stay, and vital status at discharge. The patient’s blood and biochemical tests were performed on the patient’s first day in the ICU. When there were multiple test values for a variable, the average of these values was used for analysis.

**Primary and secondary outcomes**

The primary outcome was 30- and 60-day survival in two groups: the normal APTT group and the high APTT group.

**Statistical analysis**

Categorical variables are expressed as a number (percentage) and continuous variables as a mean (SD). To compare the two groups, we used t-tests, Chi-square (χ²) tests, or Wilcoxon rank-sum tests. The survival analysis was conducted using Kaplan–Meier (KM) and Cox proportional hazard regression models. SPSS version 26 (IBM SPSS) was used for the statistical analysis. Any p < 0.05 was defined as statistically significant.

**RESULTS**

**Baseline characteristics between training cohort and validation cohort**

A total of 844 patients with AP were enrolled and randomly divided into the training cohort (n = 591) and the validation cohort (n = 253) at a ratio of 7:3. There were no significant differences between the two cohorts in gender, age, APTT values, mortality, ICU admission time, Sequential Organ Failure Assessment (SOFA) score, BISAP score, Ranson score, APACHE II score, medical histories (including diabetes, coronary heart disease, hypertension, chronic kidney disease, chronic obstructive pulmonary disease, cirrhosis, and gallstones), complications (including acute kidney injury, hepatic encephalopathy, sepsis, pleural effusion, ascites, and ventilator use), and laboratory test results (p > 0.05; Table 1). In summary, the training cohort and validation cohort were well matched in all parameters.

**Baseline characteristics of training cohort population**

A total of 591 patients with AP were enrolled in the training cohort. There were no significant differences in age, gender, etiologies, heart failure, pleural effusion, BISAP scores, Ranson score, or APACHE II score between patients in the high and normal APTT groups (p > 0.05; Table 2). Patients in the high APTT group had a higher incidence of acute kidney injury, sepsis, ascites, and disseminated intravascular coagulation (DIC; p < 0.001; Table 2). In the high APTT group, vasopressors were used more frequently and ICU stays were longer than the
### Characteristics of training and validation cohorts

| Factors                        | Training (n = 591) | Validation (n = 253) | p Value |
|-------------------------------|-------------------|----------------------|---------|
| Male                          | 344 (58.2%)       | 146 (57.7%)          | 0.893   |
| Age (year)                    | 60.2 ± 17.3       | 60.0 ± 17.8          | 0.863   |
| APTT (>37 s)                  | 144 (24.4%)       | 66 (26.1%)           | 0.596   |
| Death                         | 81 (13.7%)        | 34 (13.4%)           | 0.918   |
| ICU admission time (day)      | 6.2 ± 10.0        | 6.6 ± 11.2           | 0.567   |
| Hospital admission time (day) | 16.8 ± 16.5       | 16.9 ± 19.4          | 0.924   |
| SOFA score                    | 5.9 ± 4.1         | 6.1 ± 4.1            | 0.309   |
| BISAP score                   | 2.0 ± 0.9         | 1.9 ± 0.9            | 0.838   |
| Rason score                   | 4.1 ± 1.6         | 4.2 ± 1.6            | 0.902   |
| APACHE II                     | 26.9 ± 5.5        | 27.3 ± 5.4           | 0.649   |

#### Medical histories

|                          | Training (%)      | Validation (%)     | p Value |
|--------------------------|-------------------|--------------------|---------|
| Diabetes                 | 161 (27.2%)       | 66 (26.1%)         | 0.729   |
| Coronary heart disease   | 41 (6.90%)        | 17 (6.70%)         | 0.909   |
| Hypertension             | 99 (16.8%)        | 55 (21.7%)         | 0.086   |
| Chronic kidney disease   | 98 (16.6%)        | 53 (20.9%)         | 0.126   |
| COPD                     | 19 (3.2%)         | 10 (4.0%)          | 0.590   |
| Cirrhosis                | 60 (10.2%)        | 30 (11.9%)         | 0.462   |
| Gallstones               | 6 (1.2%)          | 1 (0.4%)           | 0.268   |

#### Complications

|                          | Training (%)      | Validation (%)     | p Value |
|--------------------------|-------------------|--------------------|---------|
| Acute kidney injury      | 292 (49.4%)       | 120 (47.4%)        | 0.599   |
| Hepatic encephalopathy  | 14 (2.4%)         | 9 (3.6%)           | 0.331   |
| Sepsis                   | 173 (29.3%)       | 71 (28.1%)         | 0.723   |
| Pleural effusion         | 86 (14.6%)        | 26 (10.2%)         | 0.083   |
| Ascites                  | 93 (15.7%)        | 37 (14.6%)         | 0.682   |
| Ventilator use           | 72 (12.2%)        | 41 (16.2%)         | 0.116   |

#### Laboratory tests

|                          | Training (%)      | Validation (%)     | p Value |
|--------------------------|-------------------|--------------------|---------|
| White blood cells (×10^3/μL) | 14.0 ± 8.1       | 14.0 ± 7.9         | 0.952   |
| Platelets (×10^3/μL)      | 225.5 ± 139.9     | 227.7 ± 138.1      | 0.836   |
| Hemoglobin (g/dL)         | 11.2 ± 2.6        | 11.5 ± 2.7         | 0.153   |
| Lymphocytes (×10^3/μL)    | 10.2 ± 8.3        | 10.7 ± 10.4        | 0.521   |
| Monocytes (×10^3/μL)      | 4.8 ± 3.0         | 5.0 ± 3.4          | 0.457   |
| Neutrophils (×10^3/μL)    | 79.9 ± 12.7       | 80.0 ± 13.8        | 0.863   |
| Hematocrit (%)            | 34.1 ± 7.5        | 34.9 ± 7.7         | 0.109   |
| Albumin (g/L)             | 3.1 ± 0.7         | 3.1 ± 0.7          | 0.854   |
| Anion gap (mmol/L)        | 17.2 ± 6.7        | 17.4 ± 5.7         | 0.667   |
| Bicarbonate (mmol/L)      | 21.2 ± 5.9        | 20.5 ± 5.2         | 0.087   |
| Sodium (mmol/L)           | 138.3 ± 5.8       | 137.1 ± 6.1        | 0.632   |
| Potassium (mmol/L)        | 4.2 ± 0.9         | 4.2 ± 0.9          | 1.000   |
| Calcium (mg/dl)           | 8.0 ± 1.2         | 7.9 ± 1.1          | 0.272   |
| Bun (mmol/L)              | 29.8 ± 27.2       | 30.0 ± 26.9        | 0.938   |
| Creatinine (mg/dl)        | 1.8 ± 2.0         | 1.9 ± 1.9          | 0.398   |
| Glucose (mg/dl)           | 163.8 ± 134.4     | 160.1 ± 123.6      | 0.722   |
| ALT (U/L)                 | 252.5 ± 936.7     | 191.0 ± 671.4      | 0.369   |
| AST (U/L)                 | 433.0 ± 1666.4    | 365.1 ± 1586.8     | 0.595   |

### Total bilirubin (μmol/L) and other laboratory tests

|                          | Training (n = 591) | Validation (n = 253) | p Value |
|--------------------------|-------------------|----------------------|---------|
| Total bilirubin (μmol/L) | 2.7 ± 4.7         | 3.4 ± 6.3            | 0.107   |
| ALP (U/L)                | 159.3 ± 155.1     | 169.7 ± 200.3        | 0.476   |
| CK-MB (ng/ml)            | 12.9 ± 37.0       | 18.8 ± 37.9          | 0.278   |
| INR                      | 1.6 ± 1.2         | 1.5 ± 1.0            | 0.244   |
| Prothrombin time (s)     | 17.6 ± 11.9       | 16.6 ± 10.8          | 0.232   |

Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; APACHE, Acute Physiology and Chronic Health Examination; APTT, activated partial thromboplastin time; AST, aspartate transaminase; BISAP, bedside index for severity in acute pancreatitis; CK-MB, creatine kinase-MB; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; INR, International Normalized Ratio; SOFA, Sequential Organ Failure Assessment.

normal group (p < 0.001; Table 2). In terms of patients in the high APTT group, SOFA scores were higher than those in the normal group (8.3 ± 4.4 vs. 5.1 ± 3.6, p < 0.001; Table 2). More importantly, the mortality rates of the patients in the high APTT group were higher than those in the normal group at 30- and 60-day follow-up (p < 0.001; Table 2). Based upon these results, it indicates that patients in the high APTT group were sicker.

#### Patients in the high APTT group have a poor short-term prognosis

The 30-day mortality is 12.9% in the training cohort, and 60-day mortality is 13.7%. The KM survival curves from both the training and validation cohorts showed that patients in the high APTT group had a lower survival probability in 30- and 60-day survival than patients in the normal group (p < 0.05; Figure 2).

In Cox regression model analysis, patients in the high APTT group continued to have higher 30- and 60-day mortality, ICU mortality, and hospital mortality than those in the normal group despite controlling for potential confounders (including age, gender, heparin, DIC, and medical history of diabetes, coronary heart disease, hypertension, chronic obstructive pulmonary disease, chronic kidney disease, and cirrhosis, p < 0.05; Table 3). The hazard ratios (HRs; 95% confidence interval [CI]) of 30- and 60-day mortality were 1.63 (1.10, 2.61, p = 0.035) and 1.49 (1.01, 2.38, p = 0.041), respectively. In line with the training cohort, the results of the validation cohort also demonstrated the above results (p < 0.001; Table 3).

After analyzing whether the DIC or sepsis affect the short-term prognosis of patients with AP by a multivariate proportional hazards model, we found that prolonged APTT was a prognostic factor for the short-term prognosis of patients...
APTT PREDICTS POOR SHORT-TERM PROGNOSIS IN AP

with AP independent of comorbid DIC or sepsis. The HR (95% CI) of 30- and 60-day mortality were 1.68 (1.06, 2.67) ($p = 0.026$) and 1.56 (1.04, 2.44) ($p = 0.041$), respectively.

### Results of subgroup analysis

Despite the difference in the HRs (95% CI) and the corresponding $p$ value in different groups, the $p$ values of the interaction test results for age, gender, diabetes, coronary heart disease, heart failure, chronic obstructive pulmonary disease, chronic kidney disease, and cirrhosis are all $>0.05$, indicating that these factors have no significant influence on the mortality of APTT. However, cirrhosis is a risk factor for death in patients with AP (Interaction $p$ value $<0.001$; Table 4). Consistent with the training cohort, the results of the validation cohort also identified the above results (Table 4).

### Prolonged APTT predicts short-term mortality performed as well as BISAP, Ranson, and APACHE II scores in patients with AP

In order to test the ability of prolonged APTT in predicting 30- and 60-day mortality in patients, we uniformly defined normal APTT as 0 and prolonged APTT as 1. After that, a receiver operating characteristic curve (ROC) analysis was carried out to compare its predictive ability with BISAP, Ranson, and APACHE II in predicting the short-term prognosis of patients with AP. In the training cohort, the extended APTT performed as well as the BISAP, Ranson, and APACHE II models in predicting the 30-day survival (area under the receiver operating characteristic curve [AUROC]: 0.661 vs. 0.633, 0.689, 0.666, respectively) and 60-day survival (AUROC: 0.658 vs. 0.634, 0.672, 0.680, respectively) in patients with AP (Figure 3a,b). Consistent with the training cohort, the results of validation cohort

---

### Table 2

Baseline characteristics of the patients with AP in the training cohort

| Factors                  | Normal APTT group | High APTT group | $p$ Value |
|--------------------------|-------------------|-----------------|-----------|
| Age (year)               | 59.9±17.4         | 61.7±16.9       | 0.256     |
| Gender                   |                   |                 |           |
| Male                     | 259 (57.9%)       | 85 (59.0%)      | 0.818     |
| Female                   | 188 (42.1%)       | 59 (41.0%)      |           |
| Etiologies of AP         |                   |                 |           |
| Unspecified              | 376 (84.3%)       | 125 (86.8%)     | 0.506     |
| Biliary                  | 35 (7.8%)         | 8 (5.6%)        |           |
| Alcohol                  | 33 (7.4%)         | 9 (6.3%)        |           |
| Drug                     | 2 (0.4%)          | 2 (1.4%)        |           |
| Acute kidney injury      |                   |                 |           |
| No                       | 246 (55.0%)       | 53 (36.8%)      | <0.001    |
| Yes                      | 201 (45.0%)       | 91 (63.2%)      |           |
| Heart failure            |                   |                 |           |
| No                       | 365 (81.8%)       | 111 (77.1%)     | 0.209     |
| Yes                      | 82 (18.2%)        | 33 (22.9%)      |           |
| Sepsis                   |                   |                 |           |
| No                       | 338 (75.6%)       | 64 (44.4%)      | <0.001    |
| Yes                      | 109 (24.4%)       | 80 (55.6%)      |           |
| Ventilator               |                   |                 |           |
| No                       | 404 (90.4%)       | 115 (79.9%)     | 0.001     |
| Yes                      | 43 (9.6%)         | 29 (20.1%)      |           |
| Pleural effusion         |                   |                 |           |
| No                       | 384 (89.9%)       | 121 (84.0%)     | 0.055     |
| Yes                      | 63 (10.1%)        | 23 (16.0%)      |           |
| Ascites                  |                   |                 |           |
| No                       | 388 (86.8%)       | 110 (76.4%)     | 0.003     |
| Yes                      | 59 (13.2%)        | 34 (23.6%)      |           |
| Vasopressors             |                   |                 |           |
| No                       | 322 (72.0%)       | 58 (40.3%)      | <0.001    |
| Yes                      | 125 (28.0%)       | 86 (59.7%)      |           |
| DIC                      |                   |                 |           |
| No                       | 446 (99.8%)       | 141 (99.3%)     | 0.018     |
| Yes                      | 1 (0.2%)          | 3 (0.7%)        |           |
| Length of stay (day)     |                   |                 |           |
| ICU                      | 5.3±7.7           | 9.0±11.7        | <0.001    |
| Hospital                 | 15.9±16.2         | 19.5±17.2       | 0.021     |
| BISAP score              | 1.9±0.9           | 2.1±1.0         | 0.150     |
| SOFA score               | 5.1±3.6           | 8.3±4.4         | <0.001    |
| Ranson score             | 4.1±1.5           | 4.4±1.6         | 0.139     |
| APACHE II                | 26.5±5.7          | 27.7±5.1        | 0.179     |
| 30-day mortality         |                   |                 |           |
| No                       | 409 (91.5%)       | 106 (74.3%)     | <0.001    |
| Yes                      | 38 (8.5%)         | 38 (25.7%)      |           |

| Factors                  | Normal APTT group | High APTT group | $p$ Value |
|--------------------------|-------------------|-----------------|-----------|
| 60-day mortality         |                   |                 |           |
| No                       | 406 (90.8%)       | 104 (72.2%)     | <0.001    |
| Yes                      | 41 (9.2%)         | 40 (27.8%)      |           |

Note: The complications listed in the table are those that occurred during the admission of the patients with acute pancreatitis. The bolded numbers indicate significance at the $p$ value $<0.05$ level.

Abbreviations: AP, acute pancreatitis; APACHE, Acute Physiology and Chronic Health Examination; APTT, activated partial thromboplastin time; BISAP, the bedside index for severity in acute pancreatitis; DIC, disseminated intravascular coagulation; ICU, intensive care unit; SOFA, Sequential Organ Failure Assessment.
also indicated that prolonged APTT performed as well as the BISAP, Ranson, and APACHE II models in predicting the 30-day survival (AUROC: 0.672 vs. 0.532, 0.648, 0.669, respectively) and 60-day survival (AUROC: 0.672 vs. 0.532, 0.648, 0.669, respectively) in patients with AP (Figure 3c,d). Based on the above results, APTT prolongation may have predictive value for predicting the short-term prognosis of patients with AP.

## DISCUSSION

Considering APTT levels are closely associated with AP, 844 patients from an extensive critical care medical database were selected for this study. After adjusting for age, gender, use of heparin, DIC, and pre-existing medical conditions, including diabetes, coronary heart disease, hypertension, chronic kidney disease, chronic obstructive
pulmonary disease, and cirrhosis, we found that patients in the prolonged APTT group had significantly higher mortality at 30 and 60 days than those in the normal group. In patients with AP, APTT prolongation was positively associated with acute kidney injury, sepsis, ventilator use, and ascites. These conditions indicate critical illness. Patients who suffer from one or more of these complications often has a poor prognosis. The results of the ROC test showed that APTT was comparable to BISAP, Ranson, and APACHE II in predicting short-term mortality in patients with AP. However, it was more straightforward and more convenient than BISAP, Ranson, and APACHE II. Although the results of the interaction test indicated that cirrhosis was a risk factor for patients with prolonged APTT, there was no statistical difference in the baseline information on cirrhosis between the normal and prolonged APTT groups. Additionally, APTT was a prognostic biomarker for the short-term prognosis of patients with AP independent of comorbid DIC or sepsis. So prolonged APTT is reliable and convincing in determining the short-term prognosis of patients with AP.

The APTT is a functional measure of the intrinsic and common pathways of the coagulation cascade. In most cases, a prolonged APTT indicates a deficiency of coagulation factors in the body or reduced activity of coagulation factors or antibodies to coagulation factors. A patient with protracted APTT is at higher risk for bleeding, particularly internal bleeding. Severe cases can lead to shock or even patient death. In addition, we found that patients with AP who had prolonged APTT had a higher incidence of DIC than those with normal APTT. Therefore, clinicians should make aware of the possibility of bleeding in patients with a prolonged APTT.

### Table 4

Subgroup analysis of the associations between all-cause mortality

| Factors       | Training cohort | Validation cohort |
|---------------|-----------------|-------------------|
|               | High vs. normal |          | High vs. normal |          |
| Age (year)    | HR (95% CI)     | p Value | p-Interaction  | HR (95% CI) | p Value | p-Interaction |
| <60           | 3.75 (1.57, 8.97) | 0.003    | 0.070         | 11.46 (1.40, 93.58) | 0.023    | 0.10         |
| ≥60           | 0.75 (0.44, 1.29) | 0.287    |               | 2.34 (0.92, 5.94)  | 0.073    |             |
| Gender        |                 |          |               |                 |          |             |
| Male          | 3.24 (1.71, 6.12) | <0.001   | 0.09         | 3.02 (1.53, 5.95)  | 0.001    | 0.067        |
| Female        | 0.97 (0.48, 1.95) | 0.927    |               | 3.10 (1.62, 6.01)  | 0.001    |             |
| Diabetes      |                 |          |               |                 |          |             |
| No            | 2.29 (1.33, 3.95) | 0.003    | 0.249        | 3.10 (1.44, 6.67)  | 0.004    | 0.332        |
| Yes           | 1.23 (0.54, 2.80) | 0.623    |               | 2.78 (0.61, 12.55)| 0.185    |             |
| CHD           |                 |          |               |                 |          |             |
| No            | 1.90 (1.19, 3.04) | 0.007    | 0.087        | 3.61 (1.75, 7.44)  | 0.001    | 0.701        |
| Yes           | 1.58 (0.35, 7.14) | 0.553    |               | 0.038 (0.00, 3.53) | 0.656    |             |
| Heart failure |                 |          |               |                 |          |             |
| No            | 2.21 (1.29, 3.78) | 0.004    | 0.285        | 3.43 (1.50, 7.84)  | 0.003    |             |
| Yes           | 1.14 (0.49, 2.66) | 0.767    |               | 1.55 (0.47, 5.09)  | 0.474    |             |
| COPD          |                 |          |               |                 |          |             |
| No            | 1.84 (1.16, 2.92) | 0.010    | 0.055        | 2.65 (1.33, 5.26)  | 0.006    | 0.061        |
| Yes           | 1.33 (0.27, 6.68) | 0.729    |               | 2.3 (0.00, 3.56)   | 0.616    |             |
| CKD           |                 |          |               |                 |          |             |
| No            | 2.21 (1.32, 3.71) | 0.003    | 0.285        | 3.84 (1.61, 9.18)  | 0.002    | 0.160        |
| Yes           | 1.20 (0.48, 3.02) | 0.695    |               | 2.44 (0.74, 8.06)  | 0.142    |             |
| Cirrhosis     |                 |          |               |                 |          |             |
| No            | 1.51 (0.91, 2.51) | 0.110    | <0.001       | 1.79 (0.77, 4.15)  | 0.173    | <0.001       |
| Yes           | 3.51 (1.98, 12.58)| 0.044    |               | 9.9 (1.26, 77.99)  | 0.029    |             |

**Note:** High vs. normal means high APTT group vs. normal APTT group.

**Abbreviations:** APTT, activated partial thromboplastin time; CHD, coronary heart disease; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; HR, hazard ratio.
mellitus, patients with elevated APTT have an increased risk of in-hospital death.\textsuperscript{18} APTT was an independent predictor of 30-day mortality in patients with septic shock caused by intra-abdominal infection admitted to the ICU.\textsuperscript{19} In sepsis, prolonged APTT significantly impacts its severity and outcome.\textsuperscript{12} Several studies have shown that prolonged APTT increases the risk of death in patients in the ICU with sepsis.\textsuperscript{11–13,20} Sepsis is associated with increased APTT, and a prolonged APTT in patients with AP indicates the possibility of sepsis, and awareness should be raised to prevent and control infection in patients. Moreover, infection, sepsis, and infectious shock are common complications of AP.\textsuperscript{21,22} Our study also found that extended APTT increases the risk of short-term death in patients with AP.

Activated partial thromboplastin time performed as well as BISAP, Ranson, and APACHE II models in predicting 30- and 60-day survival in patients with acute pancreatitis.\textsuperscript{6} (a,b) Receiver operating curves (ROC) for the abilities of risk models to predict 30- and 60-day survival of acute pancreatitis patients in training cohort; (c,d) ROC for the abilities of risk models to predict 30- and 60-day survival of acute pancreatitis patients in the validation cohort. APACHE, Acute Physiology and Chronic Health Examination; APTT, activated partial thromboplastin time; AUC, area under the curve; BISAP, bedside index for severity in acute pancreatitis.

**FUNDING INFORMATION**

No funding was received for this work.

**CONFLICT OF INTEREST**

The authors declared no competing interests for this work.

**ORCID**

Yuping Yang \(\text{https://orcid.org/0000-0001-5597-1881}\)

Biao Nie \(\text{https://orcid.org/0000-0003-1094-6767}\)

**REFERENCES**

1. Mederos MA, Reber HA, Girgis MD. Acute pancreatitis: a review. *JAMA*. 2021;325:382-390.
2. Crockett SD, Wani S, Gardner TB, Falck-Ytter Y, Barkun AN. American Gastroenterological Association Institute guideline on initial management of acute pancreatitis. *Gastroenterology*. 2018;154:1096-1101.
3. Silva-Vaz P, Jarak I, Rato L, et al. Plasmatic oxidative and metabolomic profile of patients with different degrees of biliary acute pancreatitis severity. *Antioxidants (Basel)*. 2021;10:988.
4. Xiao W, Liu W, Yin L, et al. Serum hydroxybutyrate dehydrogenase as an early predictive marker of the severity of acute pancreatitis: a retrospective study. *BMC Gastroenterol*. 2020;20:393.
5. Wu M, Shi L, Zhang H, Liu H, Liu Y, Zhang W. Predictive value of arterial blood lactic acid concentration on the risk of all-cause death within 28 days of admission in patients with severe acute pancreatitis. *Postgrad Med*. 2022;134:210-216.
6. Papachristou GI, Muddana V, Yadav D, et al. Comparison of BISAP, Ranson’s, APACHE-II and CTSI scores in predicting organ failure, complications, and mortality in acute pancreatitis. *Am J Gastroenterol*. 2010;105:435-441; quiz 442.
7. Wu BU, Johannes RS, Sun X, Tabak Y, Conwell DL, Banks PA. The early prediction of mortality in acute pancreatitis: a large population-based study. *Gut*. 2008;57:1698-1703.

8. Zhang J, Shahbaz M, Fang R, et al. Comparison of the BISAP scores for predicting the severity of acute pancreatitis in Chinese patients according to the latest Atlanta classification. *J Hepatobiliary Pancreat Sci*. 2014;21:689-694.

9. Hagjer S, Kumar N. Evaluation of the BISAP scoring system in prognostication of acute pancreatitis – a prospective observational study. *Int J Surg*. 2018;54:76-81.

10. Kamal AH, Tefferi A, Pruthi RK. How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. *Mayo Clin Proc*. 2007;82:864-873.

11. Benediktsson S, Frigyesi A, Kander T. Routine coagulation tests on ICU admission are associated with mortality in sepsis: an observational study. *Acta Anaesthesiol Scand*. 2017;61:790-796.

12. Mihajlovic D, Lendak D, Mitic G, et al. Prognostic value of hemostasis-related parameters for prediction of organ dysfunction and mortality in sepsis. *Turk J Med Sci*. 2015;45:93-98.

13. Zheng R, Pan H, Wang JF, Yu XS, Chen ZQ, Pan JY. The association of coagulation indicators with in-hospital mortality and 1-year mortality of patients with sepsis at ICU admissions: a retrospective cohort study. *Clin Chim Acta*. 2020;504:109-118.

14. Johnson A, Bulgarelli L, Pollard T, Horng S, Celi LR. MIMIC-IV (version 1.0). *PhysioNet*. 2021. doi:10.13026/s6n6-xd98

15. Ignjatovic V. Activated partial thromboplastin time. *Methods Mol Biol*. 2013;992:111-120.

16. Ji Q, Xu Q, Wang Z, Li X, Lv Q. Association between activated partial thromboplastin time, age and bleeding events in NVAF patients receiving dabigatran. *Eur J Clin Pharmacol*. 2019;75:321-328.

17. Kawabata M, Yokoyama Y, Sasano T, et al. Bleeding events and activated partial thromboplastin time with dabigatran in clinical practice. *J Cardiol*. 2013;62:121-126.

18. Iqbal A, Greig M, Arshad MF, Julian TH, Ee Tan S, Elliott J. Higher admission activated partial thromboplastin time, neutrophil-lymphocyte ratio, serum sodium, and anticoagulant use predict in-hospital COVID-19 mortality in people with diabetes: findings from two university hospitals in the U.K. *Diabetes Res Clin Pract*. 2021;178:108955.

19. Xu Z, Cheng B, Fu S, et al. Coagulative biomarkers on admission to the ICU predict acute kidney injury and mortality in patients with septic shock caused by intra-abdominal infection. *Infect Drug Resist*. 2019;12:2755-2764.

20. Benediktsson S, Hansen C, Frigyesi A, Kander T. Coagulation tests on admission correlate with mortality and morbidity in general ICU patients: an observational study. *Acta Anaesthesiol Scand*. 2020;64:628-634.

21. Boxhoorn L, Voermans RP, Bouwense SA, et al. Acute pancreatitis. *Lancet*. 2020;396:726-734.

22. Miftovic A, Pindak D, Daniel I, Pechan J. Septic complications of acute pancreatitis. *Bratisl Lek Listy*. 2006;107:296-313.

**How to cite this article:** Yang Y, Du S, Yuan W, Kou Y, Nie B. Prolonged activated partial thromboplastin time predicts poor short-term prognosis in patients with acute pancreatitis: A retrospective cohort study. *Clin Transl Sci*. 2022;15:2505-2513. doi:10.1111/cts.13378